PMC:6909918 / 22513-23147 JSONTXT

{"project":"2_test","denotations":[{"id":"31790382-23177514-69134735","span":{"begin":497,"end":498},"obj":"23177514"},{"id":"31790382-29946728-69134736","span":{"begin":603,"end":604},"obj":"29946728"}],"text":"In the present study, indirect comparisons of the three drugs showed that fruquintinib demonstrated a significant superiority for PFS when compared with TAS-102, with a similar finding also shown in the indirect comparison of DCR. These improved outcomes suggested that fruquintinb might be a better choice in selected pretreated patients with mCRC. Also, this study showed that the Eastern Cooperative Oncology Group Performance Status (ECOG PS) status of patients included in the CORRECT trial [4] (regorafenib, PS=0; 56.0%) was significantly improved when compared with patients in the FRESCO trial [7] (fruquintinib, PS=0; 27.4%)."}